Elevating Care in Moderate to Severe Atopic Dermatitis

Case Challenges

Register Now
  • Thursday, March 6, 2025
  • 7:00 pm - 8:00 pm ET
  • Room: W221 ABCDE, Level 2
  • Orange County Convention Center | Orlando, Florida
  • Hybrid
Overview

Are you keeping pace with the rapidly evolving landscape of atopic dermatitis (AD) management? Don't miss this opportunity to engage with case challenges that will test your clinical acumen and spark debates among peers. Join us for this interactive symposium that will help you refine your approach to atopic dermatitis management and improve your patient outcomes. You won’t want to miss this unique case challenge program!
Register Now
Speakers
Speaker Image
​​​​Peter Lio, MD

Clinical Assistant Professor of Dermatology & Pediatrics

​Northwestern University Feinberg School of Medicine

​Chicago, Illinois​

Speaker Image
​​​Lakshi Aldredge, MSn, ANP-BC, FAANP

​Dermatology NP

​VA Portland Health Care System

​Portland, Oregon​

Speaker Image
​​​Christopher G. Bunick, MD, PhD

​Associate Professor of Dermatology and Translational Biomedicine

​Yale University School of Medicine

​New Haven, Connecticut​

Agenda

7:00 pm

Welcome and Introductions

7:05 pm

Patient Case 1: Are Topicals Enough?

7:25 pm

Patient Case 2: Uncontrolled AD with Systemic Treatment

7:45 pm

Audience Q&A and Panel Discussion

Register Now
9800 International Drive, Room: W221 ABCDE, Level 2, Orlando, Florida, 32819
United States
Get Directions
Program Information
Learning Objectives
Upon completion of this activity, participants will:[break] [LIST] [ITEM]Identify patients with AD whose disease warrants treatment with systemic therapy[/LIST] [LIST] [ITEM]Assess impact and burden of AD in practice[/LIST] [LIST] [ITEM]Select evidence-based AD treatments that consider prior therapies and treatment goals[/LIST] [LIST] [ITEM]Advise patients on the risks/benefits of AD treatments to facilitate shared decision-making[/LIST]
Goal Statement
The goal of this activity is for learners to be better able to integrate Janus kinase (JAK) inhibitors into treatment strategies for patients with moderate to severe atopic dermatitis (AD).
Target Audience
This educational activity is intended for an audience of dermatologists, allergists & clinical immunologists, dermatology nurse practitioners/physician assistants, dermatology nurses, and primary care physicians in the United States.

The INC Program does not qualify for continuing medical education (CME) credit and is independent of the official AAD Meeting, as planned by the Scientific Assembly Committee.

Supported by an independent educational grant from AbbVie.